Literature DB >> 16825989

Impact of age and diagnosis on waiting times between important healthcare events among children 0 to 19 years cared for in pediatric units: the Canadian Childhood Cancer Surveillance and Control Program.

Julia Klein-Geltink1, Lisa Pogany, Leslie S Mery, Ronald D Barr, Mark L Greenberg.   

Abstract

BACKGROUND: The objectives were to describe and compare waiting times to diagnosis and treatment of children and adolescents who accessed pediatric oncology centers in Canada for healthcare, and to assess the effects and relative contributions of age, sex, and diagnosis to waiting times.
METHODS: Waiting times were assessed for 2,365 children (0 to 14 y) and 375 adolescents (15 to 19 y) diagnosed with cancer between 1995 and 2000 inclusive and followed by the Treatment and Outcome Surveillance system of the Canadian Children's Cancer Surveillance and Control Program. Differences were assessed using the chi2 test, Fisher exact test, and Wilcoxon test statistic.
RESULTS: Median waiting times between first assessment by treating oncologist or surgeon and definitive diagnostic procedure, and the subsequent interval to first therapeutic event, were 2 days each. Significant variation existed in both periods when stratified by age and diagnosis but not sex. The most significant differences between age groups were eliminated when stratified by diagnosis.
INTERPRETATION: This analysis suggests that once they enter the healthcare system, children and adolescents treated in pediatric centers in Canada experience short waiting times to key diagnostic and treatment events. Differences in wait times between the 2 age groups are not clinically significant and can be attributed to the differences in the types of cancer experienced by adolescents compared with children.

Entities:  

Mesh:

Year:  2006        PMID: 16825989     DOI: 10.1097/01.mph.0000212945.20480.26

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Delayed diagnosis in an adolescent with a malignant testicular tumour.

Authors:  Amani Roushdi; Mylène Bassal; Donna L Johnston
Journal:  Paediatr Child Health       Date:  2009-07       Impact factor: 2.253

2.  Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study.

Authors:  Jean-François Brasme; Martin Chalumeau; François Doz; Brigitte Lacour; Dominique Valteau-Couanet; Stephan Gaillard; Olivier Delalande; Nozar Aghakhani; Christian Sainte-Rose; Stéphanie Puget; Jacques Grill
Journal:  Eur J Pediatr       Date:  2011-05-03       Impact factor: 3.183

3.  Presenting symptoms of children with cancer: a primary-care population-based study.

Authors:  Jette Møller Ahrensberg; Rikke Pilegaard Hansen; Frede Olesen; Henrik Schrøder; Peter Vedsted
Journal:  Br J Gen Pract       Date:  2012-07       Impact factor: 5.386

4.  Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome.

Authors:  Jean-Francois Brasme; Jacques Grill; Francois Doz; Brigitte Lacour; Dominique Valteau-Couanet; Stephan Gaillard; Olivier Delalande; Nozar Aghakhani; Stéphanie Puget; Martin Chalumeau
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

5.  Symptom Interval and Patient Delay Affect Survival Outcomes in Adolescent Cancer Patients.

Authors:  Song Lee Jin; Seung Min Hahn; Hyo Sun Kim; Yoon Jung Shin; Sun Hee Kim; Yoon Sun Lee; Chuhl Joo Lyu; Jung Woo Han
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.